Lexeo Therapeutics
LXEO
90 hedge funds and large institutions have $170M invested in Lexeo Therapeutics in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 17 reducing their positions, and 15 closing their positions.
112% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 17
70% more capital invested
Capital invested by funds: $100M → $170M (+$69.9M)
42.89% more ownership
Funds ownership: 84.36% → 127.25% (+43%)
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
2% more funds holding
Funds holding: 88 → 90 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more call options, than puts
Call options by funds: $8K | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$13.2M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$11.4M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$6.93M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$6.88M |
| 5 |
Millennium Management
New York
|
+$5.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$3.9M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$2.87M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$2.24M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.9M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.48M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CC
101
Corton Capital
Carrying Place,
Ontario, Canada
| – | -$44.1K | -12,711 | Closed |
|
|
CF
102
Corebridge Financial
Houston,
Texas
| – | -$40.1K | -11,544 | Closed |
|
|
AI
103
Allostery Investments
Stamford,
Connecticut
| – | -$17.5K | -5,054 | Closed |
|
104
Comerica Bank
Dallas,
Texas
| – | -$6.11K | -1,761 | Closed |
|
|
CCM
105
Coldstream Capital Management
Bellevue,
Washington
| – | -$323 | -93 | Closed |
|
LXEO Hedge Fund Activity: Q2 2025 in Review
90 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q2 2025, worth a combined $170M — up 70% from $100M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new LXEO positions and 15 closed out — a net gain of 2 holders — while 36 added to existing stakes and 17 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $13.2M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $3.9M sold.
- 90 institutional investors held Lexeo Therapeutics (LXEO) as of Q2 2025, up from 88 in Q1 2025.
- Funds reported $170M of Lexeo Therapeutics stock for Q2 2025, up 70% quarter-over-quarter.
- 17 funds opened new Lexeo Therapeutics positions in Q2 2025 and 15 closed out, a net change of +2 holders.
- The largest Lexeo Therapeutics buyer in Q2 2025 was Balyasny Asset Management, an estimated $13.2M added.
- The largest Lexeo Therapeutics seller in Q2 2025 was Novo Holdings A/S, an estimated $3.9M sold.
Based on aggregated 13F filings for Q2 2025.